TriangleNCT04101331 · OUTCOME
European Quality of Life 5-dimensional Visual Analogue Scale Scores (EQ-5D)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- score on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- From baseline until final study visit, up to 199 weeks.
What was measured
Quality of Life (QoL) as measured by the European Quality of Life 5-dimensional questionnaire (EQ-5D) for Cohorts A. Visual Analogue Scale scores assessed based on drawn scale from 0(worst imaginable state) to 100(best imaginable state). Subjects chose their health state on scale based on their situation by themselves. A negative outcome indicates a decrease in score compared to the baseline value.
Analysis population: The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.
Groups in this outcome
Cohort A
Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).
| Group | Source count |
|---|---|
| Cohort A | 108 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A | -9.16 | 25.46 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 25.46
- value
- -9.16
- denoms
- counts
- group Id
- OG000
- value
- 108
- units
- Participants
- description
- Quality of Life (QoL) as measured by the European Quality of Life 5-dimensional questionnaire (EQ-5D) for Cohorts A. Visual Analogue Scale scores assessed based on drawn scale from 0(worst imaginable state) to 100(best imaginable state). Subjects chose their health state on scale based on their situation by themselves. A negative outcome indicates a decrease in score compared to the baseline value.
- dispersion Type
- Standard Deviation
- groups
- description
- Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).
- id
- OG000
- title
- Cohort A
- param Type
- MEAN
- population Description
- The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.
- reporting Status
- POSTED
- time Frame
- From baseline until final study visit, up to 199 weeks.
- title
- European Quality of Life 5-dimensional Visual Analogue Scale Scores (EQ-5D)
- type
- SECONDARY
- unit Of Measure
- score on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice